712results about "Carbohydrate active ingredients" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

8-Hydroxy quinoline derivative compounds for enhancing telomerase reverse transcriptase (TERT) expression, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.

The disclosure provides an extracorporeal devices, systems and methods for removing a pathogen or a toxin from a biological fluid of a subject comprising contacting a biological fluid from the subject with a loosely packed bed of adsorption media, such as a fluidized bed, wherein the adsorption media comprises heparin, to remove the pathogen or the toxin to form a treated biological fluid; and infusing the treated fluid into the subject.

Compounds that modulate the conversion of AMP to adenosine by extracellular 5'-nucleotidase, compositions containing the compounds, and methods for synthesizing the compounds are described herein. Also provided are uses of such compounds and compositions for treating and / or preventing a variety of diseases, disorders, and conditions (including cancer and immune-related disorders) mediated by extracellular 5'-nucleotidase.

In one aspect, the present disclosure provides bifunctional compounds useful for promoting or enhancing degradation of certain circulating proteins. In certain embodiments, circulating proteins mediate a disease and / or disorder in a subject, while treating or managing the disease and / or disorder entails degradation, clearance, or reduced concentration of circulating proteins in the subject. Thus, in certain embodiments, administration of a compound of the present disclosure to a subject clears circulating proteins or reduces the circulating concentration of circulating proteins, thereby treating, ameliorating or preventing a disease and / or disorder.

The present invention relates to compositions comprising polyplex formulations for delivering RNA to target organs or cells after parenteral administration, particularly after intramuscular administration. More specifically, the present invention relates to formulations for the administration of RNA, such as self-replicating RNA, particularly by intramuscular injection. More particularly, the formulations comprise polyplex particles derived from single-stranded RNA and polyalkyleneimine.

The present invention discloses a method of preparation of dry liposomes using nano-milling, homogenization followed by spray drying to enhance the bioavailability and stability of the liposomes. The method of preparation of dry liposomes comprises the steps of dissolving gum Arabic in water and nano milling the mixture, dissolving phospholipids in equal parts in water and mixing with gum Arabic, dissolving bioactive molecule in water and mixing with phospholipid mixture and gum Arabic mixture to obtain liposomal complex and nano milling the mixture. The nano milled liposome is subjected to homogenization under high pressure and the process is repeated at least three times. Finally, the homogenized liposome is dried by subjecting to spray drying to obtain a stabilized dry liposome which exhibits improved stability, solubility, absorption and hence bioavailability.

Described herein are methods of for treating and / or preventing Major adverse cardiovascular events (MACE). by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I),including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.

The present application relates to a synbiotic composition for use in the amelioration, treatment, reductions of symptoms of a neuropsychiatric disorder and / or the reduction of side effects of a pharmacological treatment of a neuropsychiatric disorder, wherein the synbiotic composition comprises at least two bacterial strains chosen from the group consisting of Lactobacillus plantarum, Lactobacillus paracasei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Bifidobacterium breve; and at least one dietary fibers chosen from the group consisting of inulin, pectin, beta-glucan, resistant starch, a galacto-oligosaccharide, an isomalto-oligosaccharide and a rice fiber.

The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.

Disclosed is a process for the synthesis of mono- and bis-nitrosylated propanediols, as well as compositions and pharmaceutical formulations that includes the compounds. The process proceeds by reacting a corresponding propanediol that is not nitrosylated with a source of nitrite, optionally in the presence of a suitable acid. When the source of nitrite is an organic nitrite, reacting step is performed in a suitable organic solvent, and when the source of nitrite is an inorganic nitrite, the reacting step is performed in a bi-phasic solvent mixture comprising an aqueous phase and a non-aqueous phase. Also disclosed are methods of treating a condition wherein administration of nitric oxide (NO) has a beneficial effect by administering said compounds, compositions or formulations.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

A method and composition for enhancing adenosine monophosphate-activated protein kinase (AMPK) activity and improving mitochondrial-related oxidative metabolism parameters in motor and sedentary mammals by oral intake of low doses of D-ribose, thereby promoting overall metabolic health in mammals.

The present invention relates to sulforaphane glycoconjugate compounds, as well as to the synthesis and therapeutic uses thereof for treating inflammatory diseases.

Provided herein are methods of ameliorating a disease or condition associated with a disorder of a complement bypass pathway by administering to a subject a complement factor B (CFB) specific inhibitor.

A topical formulation that inhibits the growth of microorganisms comprises an effective amount of an insecticide dissolved in an oil phase comprising a water-miscible or water-soluble surface active agent, a suspending agent, and a non-ionic surfactant, and an aqueous phase comprising one or more preservatives, where the aqueous phase is buffered to a specific pH. The overall antimicrobial efficacy in an emulsion formulation can be enhanced by buffering the aqueous phase of the emulsion to a pH at which the preservative system inhibits growth for a wider variety of microorganism types in the formulation relative to the equivalent formulation in which the aqueous phase is not buffered.

Provided are a composite tablet comprising a first layer containing dry granules containing sitagliptin, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and dapagliflozin, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a second layer containing wet granules containing metformin, or a pharmaceutically acceptable salt thereof, and colloidal silicon dioxide, and a method for producing the same.

Methods and compositions for improving cardiac function and health are disclosed. The methods and compositions are based on urolithin.

The present invention relates to modulators of TNF signalling for use in treating and / or preventing acute pain. In particular, a modulator of TNF signalling may be a tumour necrosis factor receptor 2 (TNFR2) agonist comprising (i) a TNFR2 binding domain comprising three TNF homology domains (THD) that specifically bind to TNFR2; and (ii) an Fc domain. The present invention further relates to combinations of a TNFR2 agonist and an inhibitor of tumour necrosis factor receptor 1 (TNFR1) signalling.

Methods, compositions and kits for reducing renal tissue toxicity in a subject caused by a kidney damaging agent are provided. The methods comprise administering to the subject: (i) a kidney damaging agent; (ii) a PPARA activator; and (iii) an inhibitor of a cellular pathway selected from the group consisting of C / EBP, PPARG, ER stress, GLUT2 and SGLT1 / 2; or (i) a kidney damaging agent; (ii) a SGLT2 inhibitor; and (iii) a PPARA activator, a C / EBP inhibitor, a PPARG inhibitor, or an ER stress inhibitor.

To solve the problem in which: in view of the role played by CD73 in cancer, as well as a diverse array of other diseases, disorders and conditions, and the current lack of CD73 inhibitors available to medical practitioners, new CD73 inhibitors, and compositions and methods associated therewith, are needed.SOLUTION: Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and / or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5'-nucleotidase, ecto is also provided.SELECTED DRAWING: Figure 1

The present disclosure is directed to methods of reducing the risk of developing Type 2 diabetes and / or treating prediabetes in a patient in need thereof, the method comprising administering to the patient, an effective amount of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, wherein the patient has an HbA1c between 5.7% to 6.4% and / or a fasting glucose between 100 to 125 mg / dl.

The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophie epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.

The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide and its use as endothelin receptor antagonist, in combination with an SGLT-2 inhibitor. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said SGLT-2 inhibitor. The invention further relates to such pharmaceutical compositions comprising crystalline forms of aprocitentan.

The present invention relates to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with pimobendan and / or telmisartan or pharmaceutically acceptable forms thereof for the prevention and / or treatment of one or more heart diseases in non-human mammals / non-human mammalian animals, such as dogs or cats.

The present invention relates to a pharmaceutical composition comprising an antibody capable of binding to the human V [gamma] 9V [delta] 2T cell receptor. The invention further relates to the use of the pharmaceutical composition of the invention for medical treatment.